S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer

Sponsor
National Taiwan University Hospital
Study ID
NCT03316326
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 79 Years
Healthy Volunteers
Not accepted

Interventions

  • Tegafur-gimeracil-oteracil potassium — DRUG
    40 mg bid, D1-14
  • Oxaliplatin — DRUG
    85 mg/m2, D1
  • Irinotecan — DRUG
    150 mg/m2, D8

Study Details

This phase II clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the Simon's two-stage optimum design. After 4 cycles of SIROX regimen, patients will proceed to curative resection.

Key Dates

Start date
Nov 1, 2017
Status verified
Oct 2017
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SIROX
    Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination

Primary Outcome Measure

resection rate [ Time Frame: 3 years ]

Central Contacts

Related Studies